GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC? | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article info

Miscellaneous

Journal club

GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC?

Free

Authors

Richard Lee PubMed articles Google scholar articles

Correspondence to Dr Richard Lee, ST4 Specialty Trainee in Respiratory Medicine and General Internal Medicine, Darent Valley Hospital NHS Trust, Kent DA2 8DA, UK; richwlee{at}gmail.com

Citation

Lee R

GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC?

Thorax 2013;68:329.

Publication history

First published July 17, 2012.

Online issue publication

September 01, 2022

Article Versions

Previous version (29 April 2016).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions